Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...

In a report released yesterday, Myles Minter from William Blair reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report). The ...

Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Tuesday, Baird analysts reiterated their Outperform rating for Axsome Therapeutics (NASDAQ:AXSM) shares, maintaining a $116.00 price target, which aligns with the broader analyst consensus showing ...

Also Read: Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says The ADVANCE-2 Phase 3 trial did not demonstrate statistical ...

Axsome Therapeutics Inc (AXSM) stock saw a decline, ending the day at $84.78 which represents a decrease of $-1.92 or -2.21% from the prior close of $86.7. The stock opened at $82 and touched a low of ...